Neuland Laboratories has suffered a setback during the fourth quarter ended March 2013 as its international sales declined. Its standalone net profit declined by 28 per cent to Rs.4.20 crore from Rs.5.83 crore in the corresponding period of last year. Its EBDITA also declined by 9.8 per cent to Rs.12.42 crore from Rs.13.77 crore. The company's standalone net sales moved down by 3 per cent to Rs.109.62 crore from Rs.112.47 crore.
For the full year ended March 2013, Neuland's standalone net sales improved marginally by 2.8 per cent to Rs.460.59 crore from Rs.448.23 crore in the previous year. Though its standalone domestic sales increased by 52 per cent to Rs.128.28 crore, its international sales declined by 8.7 per cent to Rs.332.31 crore from Rs.364.01 crore. However, its net profit went up to Rs.13.64 crore from Rs.2.03 crore. With this higher profits, its EPS worked out to Rs.17.84 as against Rs.3.36. The board of directors has announced equity dividend of 12 per cent for the year ended March 2013.
The consolidated net sales improved by 2.7 per cent to Rs.460.59 crore from Rs.448.50 crore and its net profit jumped to Rs.13.86 crore from Rs.2.56 crore. As against the equity capital of Rs.7.72 crore, its reserves & surplus moved up to Rs.92.11 crore from Rs.70.63 crore, a growth of 30.4 per cent.